SCHEMBL6420537

SCHEMBL6420537

Cc1c[nH]c2cc(C(=O)N(CC(=O)N3CCC(CN4CCCCC4)CC3)c3cccc4cccnc34)ccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.38
PKLR P30613 1/20 0.38
MAPT P10636 6/20 0.36
LMNA P02545 2/20 0.36
F10 P00742 1/20 0.35
KDM2B Q8NHM5 1/20 0.34
CNR2 P34972 2/20 0.34
GAA P10253 1/20 0.34
CNR1 P21554 1/20 0.34
THRB P10828 2/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
BRD4 O60885 1/20 0.33
ACHE P22303 1/20 0.33
HTR4 Q13639 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6421802 0.91 PKM (0.38) PKMPKLRMAPTLMNAF10
SCHEMBL6424181 0.89 F10 (0.39) MAPTLMNAF10KDM2BGAA
SCHEMBL6421346 0.85 MAPT (0.40) MAPTLMNAF10GAATHRB
SCHEMBL6423165 0.85 F10 (0.37) MAPTLMNAF10GAATHRB
SCHEMBL6422645 0.84 SMN1; SMN2 (0.40) MAPTLMNAF10KDM2BGAA
SCHEMBL6419879 0.83 MAPT (0.37) MAPTLMNAF10GAATHRB
Hydrochloric Acid SCHEMBL4840285 0.83 F10 (0.39) F10KDM4EHPGDL3MBTL1HRH3
Hydrochloric Acid SCHEMBL6420510 0.83 F10 (0.43) MAPTLMNAF10GAATHRB
SCHEMBL6421409 0.80 F10 (0.39) MAPTLMNAF10THRB
SCHEMBL5867993 0.79 LMNA (0.36) MAPTLMNAF10CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1289953-B1 SERINE PROTEASE INHIBITORS LILLY CO ELI (US) 2005-09-07 EP disclosed
US-6784182-B2 AND FACTOR XA INHIBITORS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS ELI LILLY AND COMPANY 2004-08-31 US disclosed
US-20020151724-A1 Serine protease inhibitors ELI LILLY AND COMPANY 2002-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151724-A1 Serine protease inhibitors SERPINE1, PRSS1, SERPINB1 PKM 2089/4885PKLR 398/4885MAPT 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.